CN101623282B - 一种阿司匹林双嘧达莫缓释胶囊及其制备方法 - Google Patents
一种阿司匹林双嘧达莫缓释胶囊及其制备方法 Download PDFInfo
- Publication number
- CN101623282B CN101623282B CN 200810116335 CN200810116335A CN101623282B CN 101623282 B CN101623282 B CN 101623282B CN 200810116335 CN200810116335 CN 200810116335 CN 200810116335 A CN200810116335 A CN 200810116335A CN 101623282 B CN101623282 B CN 101623282B
- Authority
- CN
- China
- Prior art keywords
- aspirin
- dipyridamole
- release
- preparation
- slow releasing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 238000013268 sustained release Methods 0.000 title claims abstract description 12
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 12
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims abstract description 46
- 229960001138 acetylsalicylic acid Drugs 0.000 claims abstract description 39
- 239000007941 film coated tablet Substances 0.000 claims abstract description 11
- 230000001154 acute effect Effects 0.000 claims abstract description 3
- 208000028867 ischemia Diseases 0.000 claims abstract description 3
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims description 36
- 229960002768 dipyridamole Drugs 0.000 claims description 32
- 239000008187 granular material Substances 0.000 claims description 23
- 238000000576 coating method Methods 0.000 claims description 21
- 239000011248 coating agent Substances 0.000 claims description 16
- 239000010410 layer Substances 0.000 claims description 12
- 238000013265 extended release Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 238000007789 sealing Methods 0.000 claims description 6
- 238000005550 wet granulation Methods 0.000 claims description 6
- 238000013270 controlled release Methods 0.000 claims description 5
- 239000000080 wetting agent Substances 0.000 claims description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 239000011247 coating layer Substances 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 3
- 238000007908 dry granulation Methods 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 206010056437 Parkinsonian rest tremor Diseases 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 229960003943 hypromellose Drugs 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000011347 resin Substances 0.000 claims description 2
- 229920005989 resin Polymers 0.000 claims description 2
- 239000011265 semifinished product Substances 0.000 claims description 2
- 239000007779 soft material Substances 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims 1
- 239000004005 microsphere Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 206010061216 Infarction Diseases 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 230000007574 infarction Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 7
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000001133 acceleration Effects 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 3
- 230000000702 anti-platelet effect Effects 0.000 description 3
- 229960001948 caffeine Drugs 0.000 description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 229960003893 phenacetin Drugs 0.000 description 3
- 241000143437 Aciculosporium take Species 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001645095 Parisis Species 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200810116335 CN101623282B (zh) | 2008-07-09 | 2008-07-09 | 一种阿司匹林双嘧达莫缓释胶囊及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200810116335 CN101623282B (zh) | 2008-07-09 | 2008-07-09 | 一种阿司匹林双嘧达莫缓释胶囊及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101623282A CN101623282A (zh) | 2010-01-13 |
CN101623282B true CN101623282B (zh) | 2012-12-05 |
Family
ID=41519377
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200810116335 Active CN101623282B (zh) | 2008-07-09 | 2008-07-09 | 一种阿司匹林双嘧达莫缓释胶囊及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101623282B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102058558A (zh) * | 2010-12-14 | 2011-05-18 | 张瑞琛 | 阿司匹林双嘧达莫双层片的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1111985A (zh) * | 1994-05-06 | 1995-11-22 | 王志刚 | 阿司匹林与潘生丁复方多层片的制备方法 |
CN1618429A (zh) * | 2003-11-19 | 2005-05-25 | 山西亚宝药业集团股份有限公司 | 一种治疗、预防中风的缓释双层片及其制备方法 |
-
2008
- 2008-07-09 CN CN 200810116335 patent/CN101623282B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1111985A (zh) * | 1994-05-06 | 1995-11-22 | 王志刚 | 阿司匹林与潘生丁复方多层片的制备方法 |
CN1618429A (zh) * | 2003-11-19 | 2005-05-25 | 山西亚宝药业集团股份有限公司 | 一种治疗、预防中风的缓释双层片及其制备方法 |
Non-Patent Citations (1)
Title |
---|
楼金芳.阿司达莫缓释胶囊的研制.《浙江大学硕士论文》.2006,第19,50-55页. * |
Also Published As
Publication number | Publication date |
---|---|
CN101623282A (zh) | 2010-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101703513B (zh) | 阿司匹林和氯吡格雷或其药学上可接受的盐的复方缓释制剂 | |
KR101324862B1 (ko) | 클로피도그렐 황산수소염의 구형 입자, 이를 포함하는 약학적 조성물 및 이의 제조방법 | |
WO2010128525A2 (en) | A formulation of ivabradine for treating the cardiovascular disease | |
CN103006649A (zh) | 一种复方制剂缬沙坦氨氯地平片(ⅰ)及其制备方法 | |
CN103655505B (zh) | 一种止痛类双层控释片及其制备方法 | |
CN113616624B (zh) | 一种恩格列净二甲双胍缓释制剂及其制备方法 | |
CN111939136A (zh) | 一种含有替格瑞洛和阿司匹林的复方制剂及其制备方法 | |
CN101259132A (zh) | 阿司匹林双嘧达莫缓释胶囊及生产方法 | |
CN101990427A (zh) | 米格列奈及二甲双胍的复合制剂及其制造方法 | |
CN101623282B (zh) | 一种阿司匹林双嘧达莫缓释胶囊及其制备方法 | |
CN102247366B (zh) | 包括依那普利和非洛地平的药物组合物缓释制剂 | |
CN101636153A (zh) | 时间特异性延迟/脉冲释放剂型 | |
CN103505460B (zh) | 一种制备氯沙坦钾氢氯噻嗪组合物的方法 | |
CN101953833A (zh) | 含苯甲酸利扎曲普坦缓控释剂型、其制备方法和用途 | |
CN102008456A (zh) | 含有美托洛尔琥珀酸盐的新型骨架缓释片 | |
CN107868009B (zh) | 一种酒石酸美托洛尔晶体及含该晶体的药物组合物及其制备方法 | |
CN101428030A (zh) | 一种复方双嘧达莫/阿司匹林缓释胶囊及其制备工艺 | |
CN103690503B (zh) | 一种双层片的制备方法 | |
CN101732269A (zh) | 一种含有单硝酸异山梨酯的分散片 | |
CN203107745U (zh) | 一种阿司匹林双嘧达莫缓释结构 | |
CN101711753A (zh) | 兰索拉唑固体制剂的制备方法 | |
CN1751689A (zh) | 一种含有阿司匹林的药物组合物的制备方法 | |
RU2303980C2 (ru) | Лекарственная форма с антиагрегационным действием и способ ее изготовления | |
CN114209675B (zh) | 一种硫酸氢氯吡格雷阿司匹林微片胶囊及其制备方法 | |
CN103169679A (zh) | 高载药量的羟苯磺酸钙药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210112 Address after: 570314 no.279 Nanhai Avenue, Xiuying District, Haikou City, Hainan Province Patentee after: AVENTIS PHARMA (HAINAN) Co.,Ltd. Address before: 100097, Wanquan mansion, 3 Jin Zhuang, Haidian District, Beijing, Sijiqing Patentee before: BEIJING D-VENTUREPHARM TECHNOLOGY DEVELOPMENT Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
DD01 | Delivery of document by public notice |
Addressee: Song Xuemei Document name: Notice of conformity |
|
DD01 | Delivery of document by public notice | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A sustained-release aspirin dipyridamole capsule and its preparation method Granted publication date: 20121205 Pledgee: Sanya Rural Commercial Bank Co.,Ltd. Pledgor: AVENTIS PHARMA (HAINAN) Co.,Ltd. Registration number: Y2024980014810 |